NCT05813730 Urinary Creatinine Excretion Time in the Neonatal Period
| NCT ID | NCT05813730 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Central Hospital, Nancy, France |
| Condition | Renal Function |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-10-30 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-10-30 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Newborn's renal function is difficult to assess and its physiology during the first days of life is still incompletely known. Studies suggest that the newborn almost completely reabsorbs creatinine during the first 48 to 72 hours of life, while at the same time it continues to produce its own creatinine. Therefore, the initial stock of creatinine at birth still increases through this production and the non or weak clearance. A better knowledge of renal physiopathology in newborns would allow to improve the therapeutic management of the infants, particularly in case of potential nephrotoxicity. No study has attempted to assess the increase in urinary creatinine excretion in neonates from a given time. Objectives: To show when urinary creatinine excretion in newborns is efficient. Results: this study mightr show an inflection point in urinary creatinine excretion illustrating the postnatal age when renal function becomes efficient.
Eligibility Criteria
Inclusion Criteria: * All full-term newborns (37WA or more) * From a physiological and spontaneous pregnancy * Good neonatal adaptation (Apgar 7 at 5 minutes of life) * Eutrophic (weight \> 10th percentile and \< 90th percentile) Exclusion Criteria: * Newborns for whom no urine sample is interpretable * Those with a significant clinical-biological anomaly * Neonates with hemodynamic disorders such as low blood pressure (median \< gestational age) or hypovolemia (shock, signs of dehydration, need for volume expansion) during the first 3 days of life
Contact & Investigator
Nathalie LAMIREAU
PRINCIPAL INVESTIGATOR
CHRU Nancy
Frequently Asked Questions
Who can join the NCT05813730 clinical trial?
This trial is open to participants of all sexes, up to 3 Days, studying Renal Function. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05813730 currently recruiting?
Yes, NCT05813730 is actively recruiting participants. Contact the research team at j.hascoet@chru-nancy.fr for enrollment information.
Where is the NCT05813730 trial being conducted?
This trial is being conducted at Nancy, France.
Who is sponsoring the NCT05813730 clinical trial?
NCT05813730 is sponsored by Central Hospital, Nancy, France. The principal investigator is Nathalie LAMIREAU at CHRU Nancy. The trial plans to enroll 40 participants.